Great Point Partners LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Great Point Partners LLC disclosed 26 US equity positions worth $153.8m in its Q2 2025 13F filing. The largest position was IONS at 12.8% of the reported book, followed by RZLT and AMLX. Against the Q1 2025 filing, it opened 6 new positions, added to 7 and reduced 8 among the top 26 holdings.
What did Great Point Partners LLC own in Q2 2025? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 12.8% | $19.8m | 500,000 | 100% | added |
| 2 | RZLT REZOLUTE INC | 8.8% | $13.5m | 3,033,462 | 264% | added | |
| 3 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 8.3% | $12.8m | 2,000,000 | 10% | added |
| 4 | LEGN LEGEND BIOTECH CORP | Healthcare | 8.1% | $12.4m | 350,000 | 153% | added |
| 5 | ABVX ABIVAX SA | 6.4% | $9.9m | 1,291,617 | -21% | reduced | |
| 6 | NGNE NEUROGENE INC | 4.7% | $7.3m | 485,859 | 3% | added | |
| 7 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 4.7% | $7.2m | 1,985,915 | -60% | reduced |
| 8 | EOLS EVOLUS INC | Healthcare | 4.3% | $6.6m | 720,118 | -24% | reduced |
| 9 | ACLXGBX ARCELLX INC | 4.3% | $6.6m | 100,000 | 122% | added | |
| 10 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.1% | $6.3m | 200,000 | -18% | reduced |
| 11 | AKERO THERAPEUTICS INC | 3.6% | $5.5m | 103,848 | – | new | |
| 12 | JBIO JADE BIOSCIENCES INC | 3.2% | $5.0m | 498,054 | – | new | |
| 13 | CYTK CYTOKINETICS INC | Healthcare | 3.2% | $5.0m | 150,000 | -59% | reduced |
| 14 | IMVT IMMUNOVANT INC | Healthcare | 2.7% | $4.2m | 262,176 | -30% | reduced |
| 15 | UNCY UNICYCIVE THERAPEUTICS INC | 2.5% | $3.8m | 796,558 | – | new | |
| 16 | 4XC1 KALVISTA PHARMACEUTICALS INC | 2.4% | $3.7m | 323,170 | -68% | reduced | |
| 17 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 2.3% | $3.5m | 1,500,000 | – | new |
| 18 | DBVT DBV TECHNOLOGIES S A | 2.2% | $3.4m | 374,679 | – | new | |
| 19 | ZURA ZURA BIO LTD | Healthcare | 2.2% | $3.3m | 3,170,194 | 0% | held |
| 20 | UPB UPSTREAM BIO INC | 2.1% | $3.3m | 300,000 | 0% | held | |
| 21 | CNTX CONTEXT THERAPEUTICS INC | 2.0% | $3.1m | 4,683,711 | 0% | held | |
| 22 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.9% | $3.0m | 225,000 | 50% | added | |
| 23 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.4% | $2.2m | 61,607 | – | new |
| 24 | PROMIS NEUROSCIENCES INC | 0.8% | $1.3m | 2,645,128 | 0% | held | |
| 25 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.6% | $986.0k | 850,000 | 0% | held |
| 26 | HELIX ACQUISITION CORP II | 0.2% | $312.0k | 29,381 | -92% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.